Dietary fructose intake and severity of liver disease in hepatitis C virus-infected patients

Journal of Clinical Gastroenterology

Volumn 47, Issue 6, 2013, Pages 545-552

  Tyson, Gia L ^a   Richardson, Peter A ^a   White, Donna L ^a   Kuzniarek, Jill ^a   Ramsey, David J ^a   Tavakoli Tabasi, Shahriar ^a   El Serag, Hashem B ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Epidemiology; Nutrition; Sugar; Viral hepatitis

Indexed keywords

FRUCTOSE;

ADULT; ARTICLE; CROSS-SECTIONAL STUDY; DIETARY INTAKE; DISEASE ASSOCIATION; DISEASE SEVERITY; EXPOSURE VARIABLE; HEPATITIS; HEPATITIS C; HUMAN; LIVER DISEASE; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; VETERAN;

CROSS-SECTIONAL STUDIES; DIETARY CARBOHYDRATES; FRUCTOSE; HEPATITIS; HEPATITIS C, CHRONIC; HUMANS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX;

EID: 84879886354     PISSN: 01920790     EISSN: 15392031     Source Type: Journal    
DOI: 10.1097/MCG.0b013e31827244d9     Document Type: Article

References (26)

1. Bray GA, Nielsen SJ, Popkin BM. Consumption of highfructose corn syrup in beverages may play a role in the epidemic of obesity. Am J Clin Nutr. 2004;79: 537-543.
2. Collison KS, Saleh SM, Bakheet RH, et al. Diabetes of the liver: the link between nonalcoholic fatty liver disease and HFCS-55. Obesity. Silver Spring. 2009;17: 2003-2013.
3. Tetri LH, Basaranoglu M, Brunt EM, et al. Severe NAFLD with hepatic necroinflammatory changes in mice fed trans fats and a high-fructose corn syrup equivalent. Am J Physiol Gastrointest Liver Physiol. 2008;295:G987-G995.
4. Ouyang X, Cirillo P, Sautin Y, et al. Fructose consumption as a risk factor for non-alcoholic fatty liver disease. J Hepatol. 2008;48: 993-999.
5. Rizkalla SW. Health implications of fructose consumption: a review of recent data. Nutr Metab (Lond). 2010;7:82.
6. Dekker MJ, Su Q, Baker C, et al. Fructose: a highly lipogenic nutrient implicated in insulin resistance, hepatic steatosis, and the metabolic syndrome. Am J Physiol Endocrinol Metab. 2010;299:E685-E694.
7. Abdelmalek MF, Suzuki A, Guy C, et al. Increased fructose consumption is associated with fibrosis severity in patients with nonalcoholic fatty liver disease. Hepatology. 2010;51: 1961-1971.
8. Negro F. Abnormalities of lipid metabolism in hepatitis C virus infection. Gut. 2010;59: 1279-1287.
9. Poynard T, Ratziu V, McHutchison J, et al. Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C. Hepatology. 2003;38: 75-85.
10. Patton HM, Patel K, Behling C, et al. The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients. J Hepatol. 2004;40: 484-490.
11. Leandro G, Mangia A, Hui J, et al. Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data. Gastroenterology. 2006;130: 1636-1642.
12. Dai CY, Huang JF, Hsieh MY, et al. Insulin resistance predicts response to peginterferon-alpha/ribavirin combination therapy in chronic hepatitis C patients. J Hepatol. 2009;50: 712-718.
13. Hourigan LF, Macdonald GA, Purdie D, et al. Fibrosis in chronic hepatitis C correlates significantly with body mass index and steatosis. Hepatology. 1999;29: 1215-1219.
14. Armstrong GL, Wasley A, Simard EP, et al. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med. 2006;144: 705-714.
15. Nordenstedt H, White DL, El-Serag HB. The changing pattern of epidemiology in hepatocellular carcinoma. Dig Liver Dis. 2010;42(suppl 3):S206-S214.
16. Watt K, Veldt B, Charlton M. A practical guide to the management of HCV infection following liver transplantation. Am J Transplant. 2009;9: 1707-1713.
17. White DL, Tavakoli-Tabasi S, Kuzniarek J, et al. Higher serum testosterone is associated with increased risk of advanced hepatitis C-related liver disease in males. Hepatology. 2011;55: 759-768.
18. Subar AF, Thompson FE, Kipnis V, et al. Comparative validation of the Block, Willett, and National Cancer Institute food frequency questionnaires: the Eating at America's Table Study. Am J Epidemiol. 2001;154: 1089-1099.
19. Thompson FE, Subar AF, Brown CC, et al. Cognitive research enhances accuracy of food frequency questionnaire reports: results of an experimental validation study. J Am Diet Assoc. 2002;102: 212-225.
20. Halfon P, Bourliere M, Deydier R, et al. Independent prospective multicenter validation of biochemical markers (fibrotest-ActiTest) for the prediction of liver fibrosis and activity in patients with chronic hepatitis C: the fibropaca study. Am J Gastroenterol. 2006;101: 547-555.
21. Poynard T, de Ledinghen V, Zarski JP, et al. Relative performances of FibroTest Fibroscan and biopsy for assessing the stage of liver fibrosis in patients with chronic hepatitis C: a step toward the truth in the absence of a gold standard. J Hepatol. 2011;56: 541-548.
22. Imbert-Bismut F, Ratziu V, Pieroni L, et al. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet. 2001;357: 1069-1075.
23. Patel K, Benhamou Y, Yoshida EM, et al. An independent and prospective comparison of two commercial fibrosis marker panels (HCV FibroSURE and FIBROSpect II) during albinterferon alfa-2b combination therapy for chronic hepatitis C. J Viral Hepat. 2009;16: 178-186.
24. Poynard T, Imbert-Bismut F, Ratziu V, et al. Biochemical markers of liver fibrosis in patients infected by hepatitis C virus: longitudinal validation in a randomized trial. J Viral Hepat. 2002;9: 128-133.
25. Poynard T, Munteanu M, Ngo Y, et al. ActiTest accuracy for the assessment of histological activity grades in patients with chronic hepatitis C, an overview using Obuchowski measure. Gastroenterol Clin Biol. 2010;34: 388-396.
26. Bedossa P, Dargere D, Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology. 2003;38: 1449-1457. Development Center of Excellence